PRESS RELEASES & ARTICLES
STAY UPDATED

Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017

November 30, 2017

Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, with a proprietary pipeline of targeted T-cell Biologics, announces winning the “Licensing Deal of the Year” award at last night’s Scrip Awards 2017.

PDF

Arsanis Announces Closing of Initial Public Offering

November 20, 2017

Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering.

PDF

Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

November 13, 2017

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering.

PDF

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

November 02, 2017
PDF

Topas Therapeutics Appoints Rupert Sandbrink as CDO and CMO

October 26, 2017
PDF

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

October 04, 2017
PDF

Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine®

September 28, 2017
PDF

Allecra Announces Initiation of a Phase 2 Clinical Trial

September 07, 2017
PDF

Immatics Initiates a Phase I trial using ACTolog

August 22, 2017
PDF

Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards

June 16, 2017
PDF

EMBL Ventures portfolio company Luxendo acquired by Bruker

May 08, 2017
PDF

Arsanis Completes $45.5 Million Series D Financing

April 26, 2017
PDF

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

April 04, 2017
PDF

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

April 04, 2017
PDF

Arsanis and Adimab Enter Into License Agreement

February 27, 2017
PDF

Arsanis Announces First Patient Dosed in Global Phase 2 Study

January 24, 2017
PDF

Crescendo partners with Genedata

January 10, 2017
PDF

Luxendo announces Series A extension

January 09, 2017
PDF

Opsona announces preliminary MDS results

December 20, 2016
PDF

Opsona receives orphan designation

October 25, 2016
PDF

Crescendo enters a collaboration with Takeda

October 10, 2016
PDF

ViraT enters collaboration with Boehringer Ingelheim

September 28, 2016
PDF

Crescendo strengthens IP portfolio

September 27, 2016
PDF

Topas Series A Financing

March 22, 2016
PDF
© EMBL Ventures 2017